Dinh Lab
Due to the heterogeneity among cancer cells, tumors, and patients regarding drug resistance, genetics, and proteomics information, cancer patients with the same type of cancer have distinct responses to the same treatment therapy. Combination drugs have been shown to improve the probability and magnitude of therapeutic response and reduce the like-hood of acquired resistance in the individual patient.
Provectus Therapeutics is a biotech start-up revolutionizing phenotypic drug discovery, exploring phenotypic heterogeneity, using cutting-edge technologies, such as Artificial Intelligence (AI) and Microfluidic Technology to develop intelligent phenotypic screening platform (iM-Hope) to rapidly identify novel combination drugs for facilitating the development of more effective personalized cancer therapies.
